AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04403841 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control
Description: The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence
Study NCT04403841 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual diabetes care alone
Description: Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
Study NCT03455504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax add in combination with fludarabine, cyratabine and idarubicine
Study NCT04179760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCM-AGH
Description: SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
Study NCT04179760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
Study NCT05386004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth-Specific Stereogram Cards (BSSC)
Description: Focus on Birth-Specific Stereogram Cards (BSSC) during uterine contractions in latent active and transitional phase
Study NCT02421640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin+TIL
Description: cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
Study NCT02421640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
Study NCT00583830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mapatumumab
Description: 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
Study NCT00583830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mapatumumab
Description: 10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
Study NCT00583830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
Study NCT00583830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
Study NCT00583830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
Study NCT00583830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
Study NCT04427410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary test
Description: Salivary test for measured of oxytocin levels
Study NCT01794897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
Study NCT01794897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
Study NCT01944176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: simvastatin, placebo
Study NCT01944176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin, placebo
Study NCT03373773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter removal
Description: After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
Study NCT00351975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV
Study NCT00351975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study NCT00351975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03344861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
Study NCT03344861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiber optic
Description: After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
Study NCT04488068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Magnetic stimulation
Description: Sham Magnetic stimulation for comparison.
Study NCT03128554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with Training and Materials
Description: Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
Study NCT03131011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV fluorescent ink
Description: The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up.
Study NCT04200664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing assessment
Description: All study participants will undergo hearing tests, including hearing-specific questionnaires
Study NCT03658616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3970
Description: Application of cream to each axilla
Study NCT03658616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (WO3988)
Description: Application of cream to each axilla
Study NCT01446497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine/Timolol mixed combination
Description: Twice per day, 1 drop at each time
Study NCT01446497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Twice per day, 1 drop at each time
Study NCT03953001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adminstration Technique using Buzzy external distractor
Description: External application of Buzzy distractor during administration of dental anesthetic
Study NCT03953001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine with 1:50,000 epinephrine
Description: Local Dental anesthetic infiltration
Study NCT03953001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine with 1:50,000 epinephrine
Description: Local Dental anesthetic infiltration
Study NCT03953001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Anesthetic
Description: 20% Benzocaine gel was applied on the area of infiltration
Study NCT03953001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Anesthetic
Description: 20% Benzocaine gel was applied on the area of infiltration
Study NCT04200664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vestibular/balance assessment
Description: Siderosis group participants will undergo vestibular/balance tests, including gait assessment and balance-specific questionnaires
Study NCT04200664 — intervention group
Intervention type: OTHER
Intervention: Quality of life assessment
Description: All study participants will be asked to complete a set of quality of life questionnaires
Study NCT04144335 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: N-803 and bNAbs
Description: Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
Study NCT04144335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803 and bNAbs
Description: Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
Study NCT04144335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK™ Cells
Description: Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
Study NCT00832169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: 1 dose of oral solution
Study NCT00436631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary management of seizures
Description: Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
Study NCT04200664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Olfactory (smell) function testing
Description: Siderosis group participants will undergo a formal smell identification testing by means of self-administered smell chart to identify the revealed scents
Study NCT04200664 — intervention group
Intervention type: GENETIC
Intervention: DNA bio-banking
Description: Siderosis group participants will be asked to provide a saliva sample for DNA bio-banking
Study NCT05495516 — intervention group
Intervention type: GENETIC
Intervention: without Intervention
Description: without Intervention
Study NCT03042039 — intervention group
Intervention type: OTHER
Intervention: New Care
Description: New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
Study NCT03005925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: Smartphone application coupled with a hand dynamometer
Study NCT02391298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Study NCT02149186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCTuS-L
Study NCT00476697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: German manufactured UVA1 emitting light system
Description: The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
Study NCT04374721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circadian gene expression evaluation
Description: patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months
Study NCT00885430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pico-Salax
Description: Two sachets of Pico-Salax given 5 hours apart
Study NCT04371549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glue (Dermabond®; Ethicon, Somerville, NJ).
Description: Arm 1: Skin after cesarean section will be closed by glue
Study NCT04371549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl
Description: Arm 2: Skin after cesarean section will be closed by running subcuticular sutures using synthetic absorbable monofilament
Study NCT00364832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration
Study NCT01754337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop system
Description: Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
Study NCT02069483 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
Study NCT02069483 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Feedback
Description: Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
Study NCT03005925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical follow up
Description: regular visits with the specialist
Study NCT01462773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
Study NCT01462773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
Study NCT03122080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture(EA)
Description: Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients.
Study NCT03122080 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
Study NCT03122080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
Study NCT00375830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: Scan to diagnose a number of bone conditions including cancer or metastasis
Study NCT00375830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-methyl diphosphonate
Description: Radiolabel for bone scan procedures
Study NCT00375830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scan
Description: Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F
Study NCT00375830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fludeoxyglucose (18F-FDG)
Description: Radiolabel for positron emission tomography scan procedures
Study NCT00375830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) scan
Description: Scan to detect \& analyze X-rays
Study NCT00826475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction MBSR
Description: Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
Study NCT00826475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
Study NCT00375830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Sodium Fluoride (18F-NaF)
Description: Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.
Study NCT00375830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
Description: Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.
Study NCT01307085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
Study NCT00375830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine
Description: A gadolinium-based contrast agent for MRI
Study NCT00375830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadofosveset
Description: A gadolinium-based contrast agent for MRI
Study NCT00375830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: A gadolinium-based contrast agent for MRI
Study NCT01675843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Description: The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
Study NCT02789618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A01
Description: Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period
Study NCT02789618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B99
Description: Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.
Study NCT02789618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: M89
Description: Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
Study NCT02848794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Irinotecan
Description: Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
Study NCT03186040 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lacosamide
Description: Sodium channel blocker
Study NCT02698566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
Study NCT02513953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic
Description: Four Port Laparoscopic cystectomy
Study NCT03031314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: barbed suture
Study NCT03031314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard suture